FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to compounds of formula (I), their pharmaceutically acceptable salts or stereoisomers as well as pharmaceutical compositions containing them, and their use in the manufacture of medicaments for treatment of cancer.
EFFECT: new compounds have been obtained that act as inhibitors of CDK4/6 and are useful in treatment of mediated diseases.
13 cl, 7 tbl, 36 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVE WITH CONDENSED RING AS A RECEPTOR INHIBITOR | 2018 |
|
RU2748993C1 |
| THIENODIAZEPINE DERIVATIVES AND THEIR USE | 2018 |
|
RU2795005C2 |
| FGFR INHIBITOR AND ITS MEDICAL USE | 2018 |
|
RU2771311C2 |
| SELECTIVE HDAC6 INHIBITORS, THEIR PRODUCTION METHOD AND THEIR APPLICATION | 2018 |
|
RU2772274C2 |
| THIOPHENE COMPOUND, ITS PRODUCTION METHOD AND ITS PHARMACEUTICAL APPLICATION | 2017 |
|
RU2709473C1 |
| SUBSTITUTED INDOLE COMPOUNDS AS REDUCING REGULATORS OF ESTROGEN RECEPTORS | 2017 |
|
RU2722441C2 |
| DERIVATIVE BASED ON DIHYDROPYRIMIDO-RING AS HBV INHIBITOR | 2015 |
|
RU2693897C2 |
| QUINOLINE DERIVATIVES AS SMO INHIBITORS | 2015 |
|
RU2695815C2 |
| CYCLIC DI-NUCLEOTIDE COMPOUNDS FOR TREATMENT OF CANCER | 2018 |
|
RU2790175C2 |
| PYRAZINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2809631C2 |
